Eli Lilly’s latest Phase 3 study, ACHIEVE-4, demonstrates that the oral GLP-1 Foundayo (orforglipron) provides significant cardiovascular protection, weight loss, and glycemic control for adults with type 2 diabetes.
Topline results from the Phase 3 BRUIN CLL-322 trial confirm that Jaypirca significantly extended progression-free survival when added to a venetoclax regimen.
Eli Lilly has officially received Foundayo FDA approval for orforglipron, the first daily non-peptide oral GLP-1 receptor agonist that offers significant weight loss results without the dietary restrictions of previous oral treatments.
Eli Lilly and Company has announced a definitive agreement to acquire Centessa Pharmaceuticals for up to $7.8 billion, signaling a major expansion into the sleep medicine market through innovative orexin receptor agonists.
EBGLYSS durable efficacy has taken center stage in the dermatology world as Eli Lilly and Company (NYSE: LLY) recently announced groundbreaking four-year data from its [Read More…]
Eli Lilly and Company announced positive topline results from TRANSCEND-T2D-1, a landmark Phase 3 clinical trial evaluating retatrutide, an investigational triple hormone receptor agonist. The trial results demonstrate [Read More…]
EBGLYSS (lebrikizumab) achieves groundbreaking Phase 3 results in children 6 months-18 years with moderate-to-severe atopic dermatitis. 63% achieved EASI-75 skin improvement. Learn about this selective IL-13 inhibitor breakthrough.
Lilly Employer Connect launches with over fifteen administrators to close the U.S. obesity care gap, offering Zepbound® at a discounted price of $449 for employers looking to expand health benefits and reduce employee out-of-pocket costs.
Eli Lilly and Company has announced breakthrough results from ACHIEVE-3, a head-to-head clinical trial that establishes orforglipron as a superior oral GLP-1 receptor agonist for type 2 diabetes management. The investigational medication outperformed oral semaglutide across all primary and key secondary endpoints, delivering clinically meaningful improvements in blood sugar control and weight loss. With FDA obesity approval expected in Q2 2026 and regulatory submissions already filed in over 40 countries, orforglipron represents a significant advancement in cardiometabolic treatment options.
Eli Lilly expands Zepbound access with FDA-approved KwikPen multi-dose device. Patients can now choose between KwikPen or single-dose vials at the same price through LillyDirect, with self-pay pricing offering 50% or greater discount compared to other GLP-1 medicines.
